Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly
Authors:
- 30 December 2022
- journal article
- editorial
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (5) , e193-e194
Abstract
David S McLaren, Robert D Murray; Paltusotine, a novel oral somatostatin receptor ligand in the management of acromegaly, The Journal of Clinical EndocrinologyKeywords
This publication has 8 references indexed in Scilit:
- ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2022
- Durable biochemical response and safety with oral octreotide capsules in acromegalyEuropean Journal of Endocrinology, 2022
- Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2022
- Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteersPituitary, 2022
- A Pituitary Society update to acromegaly management guidelinesPituitary, 2020
- Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral OctreotideThe Journal of Clinical Endocrinology & Metabolism, 2020
- Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III TrialThe Journal of Clinical Endocrinology & Metabolism, 2015
- A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport MechanismsPharmaceutical Research, 2014